Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma.

Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ.

ISRN Hematol. 2011;2011:623924. doi: 10.5402/2011/623924. Epub 2011 Jun 16.

2.

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.

Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM.

Ann Oncol. 2014 Nov;25(11):2211-7. doi: 10.1093/annonc/mdu443. Epub 2014 Sep 5.

3.

Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.

Deng XW, Zhang XM, Wang WH, Wang SL, Jin J, Fang H, Ren H, Liu YP, He XH, Dong M, Song YW, Li YX.

Ann Hematol. 2016 Aug;95(8):1271-80. doi: 10.1007/s00277-016-2696-9. Epub 2016 May 21.

PMID:
27209536
4.

Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.

Prochazka V, Faber E, Raida L, Vondrakova J, Kucerova L, Jarosova M, Indrak K, Papajik T.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):63-6.

5.

Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?

Lunning MA, Horwitz S.

Curr Treat Options Oncol. 2013 Jun;14(2):212-23. doi: 10.1007/s11864-013-0232-x.

6.

Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.

Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM.

Ann Oncol. 2004 Oct;15(10):1467-75.

PMID:
15367405
7.

Anaplastic large cell lymphoma, ALK-negative.

Ferreri AJ, Govi S, Pileri SA, Savage KJ.

Crit Rev Oncol Hematol. 2013 Feb;85(2):206-15. doi: 10.1016/j.critrevonc.2012.06.004. Epub 2012 Jul 11. Review.

8.

Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation.

Prochazka V, Faber E, Raida L, Papajik T, Vondrakova J, Rusinakova Z, Kucerova L, Myslivecek M, Indrak K.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011 Mar;155(1):63-9.

9.

Treatment of Peripheral T-Cell Lymphoma in Community Settings.

Feldman T, Farber CM, Choi K, Faria C, Goy A, Connors J, Paramanathan D, Kaur S, Schultz E, McGuire M, Goldberg SL.

Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):354-361. doi: 10.1016/j.clml.2017.05.001. Epub 2017 May 10.

PMID:
28622960
10.

Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations.

Zettl A, Rüdiger T, Konrad MA, Chott A, Simonitsch-Klupp I, Sonnen R, Müller-Hermelink HK, Ott G.

Am J Pathol. 2004 May;164(5):1837-48.

11.

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.

Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD; International Peripheral T-Cell Lymphoma Project.

Blood. 2008 Jun 15;111(12):5496-504. doi: 10.1182/blood-2008-01-134270. Epub 2008 Apr 2.

12.

Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.

Niitsu N, Okamoto M, Nakamine H, Aoki S, Motomura S, Hirano M.

Hematol Oncol. 2008 Sep;26(3):152-8. doi: 10.1002/hon.853.

PMID:
18395866
13.

[Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].

Peng YL, Huang HQ, Lin XB, Xia ZJ, Li YH, Wang W, He YJ, Pan ZH, Jiang WQ, Guan ZZ.

Ai Zheng. 2004 Aug;23(8):943-6. Chinese.

PMID:
15301720
14.

Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.

Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, Villa D, Gascoyne RD, Connors JM, Savage KJ.

J Clin Oncol. 2013 Jun 1;31(16):1970-6. doi: 10.1200/JCO.2012.44.7524. Epub 2013 Apr 22.

PMID:
23610113
15.

Peripheral T-cell lymphoma--not otherwise specified.

Savage KJ, Ferreri AJ, Zinzani PL, Pileri SA.

Crit Rev Oncol Hematol. 2011 Sep;79(3):321-9. doi: 10.1016/j.critrevonc.2010.07.007. Epub 2010 Aug 10. Review.

PMID:
20702104
16.

Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review.

Yang YT, Tai CJ, Chen C, Wu HC, Mikhaylichenko N, Chiu HT, Chen YY, Hsu YE.

PLoS One. 2016 Oct 6;11(10):e0161811. doi: 10.1371/journal.pone.0161811. eCollection 2016. Review.

17.

Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.

Gkotzamanidou M, Papadimitriou CA.

Crit Rev Oncol Hematol. 2014 Feb;89(2):248-61. doi: 10.1016/j.critrevonc.2013.08.016. Epub 2013 Sep 8. Review.

PMID:
24075060
18.

Serum IgA level, monocyte count, and international prognostic index are independently associated with overall survival in patients with HTLV-I-negative nodal peripheral T cell lymphoma.

Kato A, Imai Y, Aoki K, Tabata S, Matsushita A, Hashimoto H, Takahashi T, Ishikawa T.

Ann Hematol. 2014 Jul;93(7):1185-91. doi: 10.1007/s00277-014-2025-0. Epub 2014 Feb 14.

PMID:
24526138
19.

Treatment of Peripheral T-Cell Lymphoma: Many Shades of Gray.

Lunning MA.

Oncology (Williston Park). 2015 Aug;29(8):545-50. Review.

20.

The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma.

Hong JY, Hong ME, Choi MK, Chang W, Do IG, Jo JS, Jung SH, Park S, Kim SJ, Ko YH, Kim WS.

Anticancer Res. 2015 Apr;35(4):2465-74.

PMID:
25862915

Supplemental Content

Support Center